A targeted search for patients with chronic obstructive pulmonary disease: brief summary

Česká verzia

Authors: Vladimír Koblížek ¹; Karel Hejduk ^2,3
Authors place of work: Plicní klinika LF UK a FN Hradec Králové ¹; Institut biostatistiky a analýz, s. r. o., Brno ²; Ústav zdravotnických informací a statistiky ČR, Praha ³
Published in the journal: Vnitř Lék 2017; 63(11): 750-756
Category: Reviews

Summary

Chronic obstructive pulmonary disease (COPD) is a leading cause mortality and morbidity globally, with permanently growing prevalence. Expressive underdiagnosis and undertreatment is a general features across all European countries. Individuals with undiagnosed, symptomatic COPD had significantly increased risk of exacerbations, pneumonia, and death. Early smoking cessation is able to reduce the mortality and morbidity burden of newly diagnosed COPD individuals. These findings suggest that better initiatives for early diagnosis and early treatment of COPD are needed. A clear diagnosis of COPD requires post-bronchodilator spirometry in symptomatic mid-elderly (more than 40) aged subjects with long-lasting inhalation exposure to known risk factors.

Key words:
COPD – morbidity – mortality – screening – spirometry – underdiagnosis

Zdroje

1. Vogelmeier CF, Criner GJ, Martinez FJ et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017; 49(6): 1700214. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.50214–2017>. Erratum for Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. [Eur Respir J. 2017].

2. Koblížek V. Habilitační práce: Vliv fyzické zátěže na agregaci trombocytů u chronické obstrukční plicní nemoci. Univerzita Karlova-Lékařská fakulta: Hradec Králové 2017. Dostupné z WWW: Dostupné z WWW: <https://dspace.cuni.cz/handle/20.500.11956/91712>.

3. Pocket guide to copd diagnosis, management, and prevention. A Guide for Health Care Professionals. 2017 REPORT. Dostupné z WWW: <http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf>.

4. Bestall JC, Paula EA, Garroda R et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54(7): 581–586.

5. Kokturk N, Kilic H, Baha A et al. Sex Difference in Chronic Obstructive Lung Disease. Does it Matter? A Concise Review. COPD 2016; 13(6): 799–806.

6. Martinez CH, Diaz AA, Parulekar AD et al. Age-related differences in health-related quality of life in COPD: an analysis of the COPDGene and SPIROMICS cohorts. Chest 2016; 149(4): 927–935. Dostupné z DOI: <http://dx.doi.org/10.1016/j.chest.2015.11.025>.

7. Celli B, Blasi F, Gaga M et al. Perception of symptoms and quality of life – comparison of patients‘ and physicians‘ views in the COPD MIRROR study. Int J Chron Obstruct Pulmon Dis 2017; 12: 2189–2196. Dostupné z DOI: <http://dx.doi.org/10.2147/COPD.S136711>.

8. McGarvey L, Morice AH, Smith JA et al. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respir Res 2016; 3(1): e000148. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjresp-2016–000148>.

9. Nakken N, Janssen DJ, van den Bogaart EH et al. Patient versus proxy-reported problematic activities of daily life in patients with COPD. Respirology 2017; 22(2): 307–314. Dostupné z DOI: <http://dx.doi.org/10.1111/resp.12915>.

10. Cannon DT, Coelho AC, Cao R et al. Skeletal muscle power and fatigue at the tolerable limit of ramp-incremental exercise in COPD. J Appl Physiol 2016; 121(6): 1365–1373. Dostupné z DOI: <http://dx.doi.org/10.1152/japplphysiol.00660.2016>.

11. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184(6): 625–626.. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201106–1136ED>.

12. Koblizek V, Milenkovic, B, Barczyk A et al. Phenotypes of COPD patients with a smoking history in Central and Eastern. Eur Respir J 2017; 49(5). pii: 1601446. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.01446–2016.>.

13. Müllerova H, Maselli DJ, Locantore N et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015; 147(4): 999–1007. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14–0655>.

14. da Silva SM, Paschoal IA, De Capitani EM et. al. COPD phenotypes on computed tomography and its correlation with selected lung function variables in severe patients. Int J Chron Obstruct Pulmon Dis 2016; 11: 503–513. Dostupné z DOI: <http://dx.doi.org/10.2147/COPD.S90638>.

15. Hurst JR, Elborn JS, De Soyza A et al. COPD-bronchiectasis overlap syndrome. Eur Respir J 2015; 45(2): 310–313. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00170014>.

16. Vellas B, Fielding R, Bhasin S et al. Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2016; 5(4): 194–200.

17. Stewart Coats AJ, Shewan LG. A comparison of research into cachexia, wasting and related skeletal muscle syndromes in three chronic disease areas. Int J Cardiol 2017; 235: 33–36. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2017.02.136>.

18. Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34(3): 648–654. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00102509>.

19. Macklem PT. The terapeutic implications of the pathophysiology of COPD. Eur Respir J 2010; 35(3): 676–680. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00120609>.

20. Boutou AK, Shrilkrishna D, Tanner RJ et al. Lung function indices for predicting mortality in COPD. Eur Respir J 2013; 42(3): 616–625. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00146012>.

21. Lange P, Celli B, Agusti A et al. Lung function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373(2): 111–122. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1411532>.

22. Rossi A, Butorac-Petanjek B, Chilosi M et al. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societes. Int J Chron Obstruct Pulmon Dis 2017; 12: 2593–2610. Dostupné z DOI: <http://dx.doi.org/10.2147/COPD.S132236>.

23. Frantz S, Nihlén U, Dencker M et al. Impulse oscilometry may be of value in detecting early manifestations of COPD. Respir Med 2012; 106(8): 1116–1123. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rmed.2012.04.010>.

24. Ofir D, Laveneziana O, Webb KA et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177(6): 622–629.

25. Elbehairy AF, Ciavaglia CE, Webb KA et al. Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease: implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med 2015; 191(12): 1384–1394. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201501–0157OC>.

26. Crook S, Büsching G, Schultz K et al. A multicentre validation of the 1-min sit-to-stand test in patients with COPD. Eur Respir J 2017; 49(3). pii: 1601871. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.01871–2016>.

27. Llordés M, Jaén A, Almagro P et al. Prevalence, risk factors and diagnostic accuracy of COPD among smokers in primary care. COPD 2015; 12(4): 404–412. Dostupné z DOI: <http://dx.doi.org/10.3109/15412555.2014.974736>.

28. Lamprecht B, Soriano J, Studnicka M et al. [BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team, and the PREPOCOL Study Group; BOLD Collaborative Research Group the EPI-SCAN Team the PLATINO Team and the PREPOCOL Study Group]. Determinants of Underdiagnosis of COPD in national and international surveys. Chest 2015; 148: 971–985. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.14–2535>.

29. Castillo D, Burgos F, Guayta R et al. FARMAEPOC group. Airflow obstruction case finding in community-pharmacies: a novel strategy to reduce COPD underdiagnosis. Respir Med 2015; 109: 475–482. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rmed.2015.02.009>.

30. Zhang J, Zhou JB, Lin XF et al. Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population. Respirology 2013; 18(2): 297–302. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1440–1843.2012.02282.x>.

31. Xu W, Collet J, Shapiro S et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35(5): 1022–1030. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00079409>.

32. Langsetmo L, Platt RW, Ernst P et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177(4): 396–401.

33. Koblizek V, Novotna B, Zbozinkova Z et al. Diagnosing COPD: advances in training and practice – a systematic review. Adv Med Educ Pract 2016; 7: 219–231. Dostupné z DOI: <http://dx.doi.org/10.2147/AMEP.S76976>.

34. Pallari E, Lewison G, Sullivan R. How is chronic non-communicable respiratory conditions research reported in European newspapers? An impact assessment for policy. Clin Respir J 2017; 11(5): 657–665. Dostupné z DOI: <http://dx.doi.org/10.1111/crj.12685>.

35. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Dostupné z WWW: <https://www.nice.org.uk/guidance/CG101/chapter/1-Guidance#diagnosing-copd>.

36. Josephs L, Culliford D, Johnson M et al. Improved outcomes in ex-smokers with COPD: a UK primary care observational cohort study. Eur Respir J 2007; 49(5). pii: 1602114. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.02114–2016>.

37. Colak Y, Afzal S, Nordestgaard BG et al. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med 2017; 5(5): 426–434. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(17)30119–4>.

38. Capozzolo A, Castellana G, Dragonieri S et al. Voluntary lung function srceening to reveal new COPD cases in southern Italy. Int J Chron Obstruct Pulmon Dis 2017; 12: 2035–2042. Dostupné z DOI: <http://dx.doi.org/10.2147/COPD.S136357>.

39. Jordan RE, Adab P, Sitch A et al. Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial. Lancet Respir Med 2016; 4(9): 720–730. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(16)30149–7>.

40. Health Screening Services. What To Expect. Screening Packages. Health Screening Videos. What Experts Say About Cardiovascular Disease. Dostupné z WWW: <http://www.lifelinescreening.com/What-We-Do/What-We-Screen-For/COPD>.

41. 41.Guillien A, Soumagne TE, Puyraveau M et al. Case-Finding for Persistent Airway Obstruction in Farmers: A Questionnaire With Optimal Diagnosis Criteria. Am J Prev Med 2017. pii: S0749–3797(17)30361–6. In press. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amepre.2017.06.031>.

42. Koblizek V, Svoboda M. Current position of new fixed-dose combination of tiotropium and olodaterol – its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic. Vnitř Lék 2016; 62(12): 1011–1020. Article in Czech.